Add description, images, menus and links to your mega menu
A column with no settings can be used as a spacer
Link to your collections, sales and even external links
Add up to five columns
Add description, images, menus and links to your mega menu
A column with no settings can be used as a spacer
Link to your collections, sales and even external links
Add up to five columns
November 11, 2025 1 min read
The Pumani bubble CPAP is a rugged, long-lived machine that works in places as diverse as Malawi, Haiti and DRC. In fact, the device is in use in over 35 countries and counting. Some of the original machines are still successfully in use a decade later.
A bubble CPAP is used to treat infants with respiratory distress syndrome. A recent study found over 1600 peer-reviewed studies on bubble CPAPs as a therapy for respiratory distress syndrome in children 1 to 59 months. This study notes which contexts in which bubble CPAP is most appropriate including the following:
The Pumani bubble CPAP was engineered by a team at Rice University in Texas, working in collaboration with clinicians in Malawi. A range of specific design considerations made the Pumani especially appropriate for low-resource settings so that the machine is easy to use and parts are easy to replace using local biomedical engineers. The Pumani bubble CPAP arrives with some spare parts already included inside the machine itself.
Simple videos by Picturing Health make the introduction and set-up of the Pumani bubble CPAP approachable and intuitive.
Comments will be approved before showing up.
May 25, 2026 1 min read
High quality ISO 13485 and CE-marked Non-pneumatic anti shock garments (NASG) produced by Maternova for use by midwives and obstetricians all over the world to save lives threatened by postpartum hemorrhage. Our NASGS adhere to the highest standards and are trusted by hundreds of clinicians.
May 25, 2026 2 min read
A 2025 study at a Federally Qualified Health Center (FQHC) serving a socially vulnerable population proved that with implementation of a universal low dose aspirin protocol, adherence jumped from 8.7% to 75%.